Targeted engineering strategies include deletion of toxic genes, such as thymidine kinase (TK), A35, or A49, and insertion of tumor-specific elements to enhance tissue selectivity and antitumor potency [85,86,87,88,89,90,91]. The gene discussed is TKT; the disease is neoplasm.